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Summary. Primary and secondary bone tumors clearly
deteriorate quality of life and the activity of daily living
of patients. These undesirable diseases become a major
social and economic burden. As both primary and
secondary bone tumors develop in the unique bone
tissue, it is therefore necessary to understand bone cell
biology in tumor bone environment. Recent findings of
the Receptor Activator of Nuclear Factor-κB ligand
(RANKL)/RANK/osteoprotegerin (OPG) molecular
triad, the key regulators of bone remodeling, opened new
era of bone research. Although RANK is an essential
receptor for osteoclast formation, activation and
survival, functional RANK expression has been recently
identified on several bone-associated tumor cells. When
RANK is expressed on secondary bone tumor cells, it is
implicated in tumor cell migration, whereas this is not
the case for primary bone tumors. In any case, RANK is
not involved in RANK-positive cell proliferation or
death. In two models of bone metastases secondary to
melanoma or prostate carcinoma, in vivo neutralization
of RANKL by OPG resulted in complete protection from
paralysis, due to metastases of vertebral body, and a
marked reduction in tumor burden in bones, but not in
other organs. OPG also decreased tumor formation and
tumor burden in a mouse model of primary bone tumor,
osteosarcoma. In all these models, tumor cells express
RANK. These data revealed that local differentiation
factors, such as RANKL, play an important role in cell
migration in a metastatic tissue-specific manner. These
findings substantiate the novel direct role of
RANKL/RANK in bone-associated tumors, and its
capability of representing new therapeutic targets.
Key words: RANK, RANKL, Bone metastasis,
Migration
Introduction 
Cancer is one of the major causes of death all over
the world. Bone is a well-known target organ of cancer
metastasis, resulting in severe pain, pathological
fractures, nerve palsy and hypercalcemia (Coleman,
1997). Cancers induce marked deterioration of quality of
life (QOL) and the activity of daily living (ADL) of
patients. Thus, the social and economic burden of this
disease is progressively increasing. As a result of the
improved survival of patients with cancers by means of
significant advances in primary cancer site control, much
attention has been paid to cancer bone metastases.
Primary bone tumors such as osteosarcoma are also
significant concerns, as well as metastatic ones.
Aggressive chemotherapy has improved survival of
osteosarcoma patients compared with the pre-
chemotherapeutic era. Overall survival of non-metastatic
patients at 5 years has improved to 60-70%, but has
reached a plateau since the mid-1980s (Meyers et al.,
2005). As the response of the tumor cells to
chemotherapy drugs governs the survival of patients
with osteosarcoma, multi-drug resistance is a major
problem in osteosarcoma treatment. Thus, a
breakthrough in the treatment of both primary and
secondary bone tumors is really needed.
Since the late nineteenth century, it has been thought
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Cellular and Molecular Biology
that the microenvironment of the local host tissue
actively participates in the propensity of certain cancers
to metastasize to specific organs (Paget, 1889), but the
specific factors involved are unknown.
Because bone tumors develop in a unique tissue,
bone, bone cell biology must be taken into account.
Bones are constantly remodelled throughout life by two
complementary processes: bone matrix formation being
regulated by osteoblasts and bone resorption by
osteoclasts. The precise inter-relation between
osteoblasts and osteoclasts leading to osteoclastogenesis
is still partly unknown. However, the discovery of key
factors involved in the control of osteoclastogenesis has
moved bone research into a new era. Notably, factors
belonging to the tumor necrosis factor (TNF)/TNF
receptor family are: Receptor Activator of Nuclear
Factor-κB (RANK/TNFRSF11A), its ligand
RANKL/TNFSF11 and a decoy receptor for RANKL,
osteoprotegerin (OPG/TNFRSF11B) (Anderson et al.,
1997; Simonet et al., 1997; Lacey et al., 1998; Yasuda et
al., 1998). Consequently, RANK expressed on
osteoclasts/osteoclast precursor cells is an essential
signaling receptor for osteoclastogenesis (Nakagawa et
al., 1998). RANKL has been shown to both mediate
osteoclastogenesis and activate mature osteoclasts,
whereas OPG negatively regulates RANKL binding to
RANK and reduces the half-life of membranous
RANKL, therefore inhibiting bone resorption induced by
osteoclasts (Tat et al., 2006). 
Current findings have revealed that the
RANKL/RANK/OPG molecular triad represents the key
regulator, not only for normal, but also for pathological
bone metabolism (Brown et al., 2001; Goltzman, 2001;
Chen et al., 2006). The prevention of metastatic bone
tumors by RANKL inhibitors [i.e., OPG or soluble
RANK(sRANK)/RANK-Fc] in animal models of bone
metastases highlights the critical role of this triad in
cancer-induced bone manifestations (Zhang et al., 2001,
2003; Corey et al., 2005; Whang et al., 2005; Canon et
al, 2007; Mountzios et al., 2007). These anti-tumor
effects were only observed in bone, not in other tissues,
such as subcutaneous models (Zhang et al., 2001, 2003).
Thus, it has been believed that the anti-tumor effect
induced by blocking RANKL/RANK interaction was the
result of an indirect effect via osteoclasts.
Interestingly, functional RANK expression was
recently reported in some bone-associated tumors and
tumor cells (Jones et al., 2006; Wittrant et al., 2006;
Mori et al., 2007a,b; Armstrong et al., 2008). As the
migration of RANK-positive tumor cells was induced by
RANKL stimulation (Jones et al., 2006; Mori et al.,
2007c; Armstrong et al., 2008), the direct effect of
RANKL on RANK-positive tumor cells has attracted
special attention.
In this review, we update the accumulating evidence
of RANK expression on cancer cells and its capability to
be considered as a new therapeutic target to block
RANKL induced bone resorption and therefore tumor
progression.
RANK expression
RANK expression and its critical role in osteoclast
formation, activation and survival are common
knowledge. However, its expression has also been
detected in other tissues, including mammary gland,
lung, kidney and skeletal muscle (Theoleyre et al.,
2004). Genetically, RANK is essential for the
development of the lactating mammary gland during
pregnancy (Fata et al., 2000) and for lymph node
organogenesis in mouse embryos (Kong et al., 1999).
However the role of RANK in other tissues is far from
being completely understood.
The results of recent studies have opened the door to
a new stage of RANK-related research. Namely,
ourselves (Wittrant et al., 2006; Mori et al., 2007a,b) and
other groups (Jones et al., 2006; Armstrong et al., 2008)




Osteosarcoma, the most frequent primary malignant
bone tumor which originates from mesenchymal cells is
characterized by a direct malignant osteoid and/or
woven bone formation by tumor cells (Herzog, 2005),
with approximately 1000 new cases per year both in
North America and in Europe (Stiller et al., 2006). 
Formerly, several studies reported RANK expression
on osteoblastic cells at the transcript level without
corresponding protein expression and functionality.
However, the results were controversial (Huang et al.,
2000; Miyamoto et al., 2002; Bu et al., 2003; Rifas et al.,
2003). We first reported the expression of functional
RANK on the POS-1 murine osteosarcoma cell line
(Wittrant et al., 2006). Subsequently, we also revealed
positive functional RANK expression in several human
osteosarcoma cell lines, including MG-63, Saos-2 and
MNNG/HOS, but not in U-2 OS (Mori et al., 2007b).
This discrepancy might be explained, at least, by the
heterogeneous population of osteosarcoma cell lines
used which can lose some of their properties when
cultured for a long time in vitro (Narita et al., 1996).
Furthermore, RANK is also detected in 11 out of 19
(57%) Caucasian osteosarcoma specimens, with a
preferential expression in bad responders to standard
chemotherapy as evaluated by Huvos score (Mori et al.,
2007b). Although RANK is a membranous receptor,
three types of localization were observed: nuclear,
cytoplasmic and concomitantly in the nucleus and
cytoplasm (Fig. 1). This is the first report on RANK
distribution. Among 11 specimens of RANK-positive
human osteosarcoma, RANK staining was localized to
the cytoplasm (27%), nucleus (27%) or both
compartments (46%). No apparent correlation was
revealed between RANK status and age, sex,
histological type and tumor localization (Mori et al.,
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2007b). 
Although nuclear RANK localization has not been
formerly reported, this finding is not unprecedented. In
fact, other membrane-associated growth factor receptors
have been recently reported to function in the nucleus.
This is the case for EGF (Lin et al., 2001) and FGF
(Peng et al., 2002) receptors and other TNF receptor
family members, including TNF-related apoptosis
inducing ligand (TRAIL) receptors (Zhang et al., 2000)
and the CD40 receptor (Lin-Lee et al., 2006). The
signalosome associated with the TNF family has been
also observed in the nucleus [e.g. TRAFs, NF-κB
proteins, etc. (Min et al., 1998; Anest et al., 2003)],
suggesting the potential nuclear migration of signaling
pathway components after the binding of ligands from
the TNF family to their membrane receptors.
Secondary (metastatic) bone tumors
Breast cancer
Breast cancer is the major cause of death among
women worldwide. Bone metastasis occurs in 16-73% of
breast cancer patients. Breast cancer keenly metastasizes
to bone to form osteolytic lesions, which are mediated
either directly by tumor cells or indirectly by osteoclasts
(Guise, 2000; Käkönen and Mundy, 2003). However the
factors favoring breast cancer growth in bone remain to
be resolved.
Expression of RANK at the cell surface of three
different human breast cancer cell lines (MDA-MB-231,
MCF-7 and Hs578T) was detected by flow cytometry
analysis (Jones et al., 2006) and by immunohisto-
chemistry on human breast cancer cells at the site of the
primary tumor and in lymph node metastases (Jones et
al., 2006). Since RANK is expressed in normal
mammary gland and has an essential role in the
development of the lactating mammary gland during
pregnancy (Fata et al., 2000), it could be hypothesized
that malignant breast cancer cells also express RANK.
Prostate cancer
Prostate cancer is the most common cancer
diagnosed in men, currently the major leading cause of
cancer death (Landis et al., 1999; Mundy, 2002).
Prostate cancer metastases to bone are observed in
approximately 80% of patients and are associated with
significant morbidity and mortality (Landis et al., 1999;
Mundy, 2002). Unlike other solid tumors that are
associated with osteolytic bone metastases, prostate
cancer bone metastases stimulate an overall increase in
both bone remodeling and bone volume (Kawano et al.,
1989). Recent findings also strongly suggest the
importance of osteoclast function in osteoblastic tumors
(Zhang et al., 2001, 2003; Corey et al., 2005; Whang et
al., 2005). However, the mechanisms underlining these
processes are not fully determined.
RANK expression was analyzed by flow cytometry
or immunohistochemistry on the cell surface of six
prostate cancer cell lines established from a variety of
disease stages: primary tumor (22Rv1), lymph node
(LNCaP), brain (DU145) or bone (PC3, MDAPCa2b and
C42B) metastases (Jones et al., 2006; Mori et al., 2007c;
Armstrong et al., 2008). Four out of six cell lines (PC3,
DU145, LNCaP and C42B) were RANK-positive both at
the transcript and protein levels, whereas 22Rv1 and
MDAPCa2b were RANK-negative at the mRNA level
(Armstrong et al., 2008). As the RANK-positive cell
lines were isolated from both androgen-dependent
(LNCaP) and -independent (PC3, DU145 and C42B)
tumors, it appeared that RANK expression on prostate
cancer cells is not related to androgen-dependency.
Malignant melanoma
Melanoma now accounts for 5% of all cancers
diagnosed. According to the American Cancer Society,
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Fig. 1. Representative RANK immunostaining in human osteosarcoma samples. RANK can be localized in the nucleus (A), cytoplasm (B) or
concomitantly in both cytoplasmic and nuclear compartments (C) of tumor cells. Original magnifications, x 400
an estimated 59,940 new cases of melanoma were
diagnosed in 2007, and approximately 8,110 patients
will die of this disease (Jemal et al., 2007). In contrast to
most metastatic bone tumors, including breast cancers,
malignant melanoma metastasize to bone without
stimulating osteoclastic bone resorption (Arguello et al.,
1988). Notably, a mouse B16F10 melanoma subclone
does not trigger osteoclast activation (Sanchez-
Sweatman et al., 1997), but expresses high levels of
RANK both at the mRNA and protein levels (Bakewell
et al., 2003; Jones et al., 2006). Jones et al. therefore
used this subclone in an in vivo study to demonstrate the
involvement of RANK on the bone metastases process
(Jones et al., 2006).
Downstream signal transduction of RANK
Downstream signal transduction pathways of RANK
were analyzed using RANKL on RANK-positive bone-
associated tumors (Jones et al., 2006; Mori et al.,
2007b,c; Armstrong et al., 2008). RANKL treatment
induced dose-dependent activation of extracellular
signal-regulated kinases 1 and 2 (ERK1/2), p38, Jun-
kinase (JNK), NF-κB, phospholipase C (PLC), protein
kinase C (PKC), protein kinase B (PKB/AKT) and
phosphatidylinositol 3-kinase (PI3-K) via their
phosphorylation (Fig. 2). Furthermore, as RANKL-
inhibitors (OPG or sRANK/RANK-Fc) blocked these
activations, these signaling pathways were recognized as
RANKL specific, reinforcing the hypothesis that RANK
is functional on these tumor cells.
Biological function of RANK expressed on tumor
cells
To summarize the knowledge from recent studies, it
appears that the biological function of RANK expressed
on tumor cells differs according to their origin (primary
or secondary bone tumors).
RANKL-induced cell migration in vitro was
confirmed in three different human breast cancer cell
lines (MDA-MB-231, MCF-7 and Hs578T), two prostate
cancer cell lines (PC3 and DU145) and a mouse B16F10
melanoma subclone (Jones et al., 2006; Mori et al.,
2007c; Armstrong et al., 2008). In vitro migrations of
cancer cells was evaluated in Boyden chambers (Jones et
al., 2006; Armstrong et al., 2008) or by slit assay (Mori
et al., 2007c). This RANKL-induced cell migration is
concentration-dependent and is blocked by RANKL-
inhibitors (OPG or sRANK/RANK-Fc). The specific
signal transduction pathways responsible for RANK-
positive tumor cell migration were determined using
several specific inhibitors. Thus, ERK1/2, PLC, PKC
and PI3-K signaling pathways were involved in
RANKL-induced cell migration in RANK-positive
tumor cells (Jones et al., 2006; Mori et al., 2007c;
Armstrong et al., 2008) (Fig. 2).
Moreover, Armstrong et al. demonstrated that
RANKL stimulation alters the gene expression that
governs chemotaxis, migration and invasion of PC3
prostate cancer cells using microarray and quantitative
RT-PCR (RT-qPCR) (Armstrong et al., 2008). Among
14,500 genes analyzed, 42 genes were significantly
(greater than twofold, p<0.05) regulated by RANKL
treatment (Armstrong et al., 2008).
Since the mouse B16F10 melanoma subclone used
by Jones et al. does not trigger osteoclast activation, it
allowed the authors to uncouple the direct effects of
RANKL on tumor metastasis from osteoclast-mediated
effects (Jones et al., 2006). In vivo inhibition of RANKL
with the decoy receptor OPG resulted in a marked
reduction of the melanin-producing B16F10 cancer foci
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Fig. 2. Schematic presentation of the
downstream signal transduction pathways
activated by RANKL in RANK-positive cells.
Extracellular signal-regulated kinases 1 and 2
(ERK1/2), phospholipase C (PLC), protein
kinase C (PKC) and phosphatidylinositol 3-
kinase (PI3-K) are involved in RANKL-induced
RANK-positive tumor cell migration. Jun-kinase
(JNK), p38 and protein kinase B (PKB/AKT) are
involved in so far unknown mechanisms.
and tumor burden in a bone-specific fashion, as the
tumor burden and metastasis of B16F10 melanoma cells
into other tissue, including ovaries, adrenal glands and
the brain were not attenuated by OPG treatment. In
addition, OPG treatment reduced the tumor burden in
vertebrae, which resulted in spinal cord invasion
followed by clinical paralysis, and none of the OPG-
treated mice developed clinical paralysis. Moreover,
control mice injected with B16F10 cells showed high
morbidity compared to OPG-treated mice. Thus, in vivo
inhibition of RANKL by OPG can abrogate metastasis
and tumor burden of B16F10 melanoma cells selectively
in bones.
In contrast to these tumor cells, cell migration of
RANK-positive osteosarcoma cells was not triggered by
RANKL (Mori et al., 2007b). In RANK-positive POS-1
cells, RANKL induced expression of bone
morphogenetic protein (BMP)-2 and slightly inhibited
osteosarcoma cell proliferation (Wittrant et al., 2006).
As a substitute, we also revealed a direct gene
modulation by RANKL on RANK-positive Saos-2
human osteosarcoma cells, which was confirmed by RT-
qPCR (Mori et al., 2007a). Briefly, 69 genes out of 6,864
cancer-related genes analyzed showed significantly
different levels of expression in RANKL-treated Saos-2
cells compared to the control group: 48 were down-
regulated, whereas the remaining 21 were up-regulated.
The down-regulated group involved some genes
implicated in protein metabolism, nucleic acid
metabolism, intracellular transport, cytoskeleton
organization and biogenesis, as well as apoptosis and
signaling cascade. In the up-regulated group, the main
genes affected by RANKL as referred to ontology
biological processes were nucleic acid and protein
metabolisms. Some genes shifted towards osteosarcoma
development, whereas others towards its suppression.
Further experiments are needed to determine the balance
between pro- and anti-tumor activities of RANKL in
osteosarcoma.
Alternatively, OPG treatment in the mouse POS-1
osteosarcoma model not only prevented osteosarcoma-
induced osteolysis, but also indirectly inhibited tumor
development, leading to a longer survival of OPG-
treated animals (Lamoureux et al, 2007). Since POS-1
cells express RANK but not RANKL, these results
indicate that RANKL has a propensity for osteosarcoma
development in bone tumor environment.
RANKL-induced downstream signal transduction
pathways of RANK, such as PKB/AKT, ERK1/2, p38,
are frequently involved in cell proliferation and growth.
However, RANKL had no apparent effects on
proliferation or death of RANK-positive tumor cells
(Jones et al., 2006; Mori et al., 2007b,c; Armstrong et
al., 2008).
Conclusion
There is considerable experimental evidence that
bone microenvironment provides reciprocal feedback
leading to the formation of a vicious cycle that supports
tumor growth and occurs in both osteolytic and
osteoblastic bone metastases (Roodman, 2004). This
vicious cycle has been proposed to explain tumor
development in bone sites. Indeed, current studies have
disclosed that blocking RANKL, RANK interaction
prevents the progression of both breast and prostate
cancer in bone by preventing bone degradation due to
osteoclasts (Zhang et al., 2001, 2003; Corey et al., 2005;
Whang et al., 2005; Canon et al., 2008; Mountzios et al.,
2007).
In metastatic bone tumors, RANKL might have a
propensity for bone-metastases development by
synergistic effect on osteoclast activity, acting as a “soil”
factor in bone environment. On the contrary, the exact
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Fig. 3. Schematic presentation of the tumor
bone environment. RANKL induces RANK-
posit ive secondary bone tumor cells
migration, but not in RANK-positive primary
bone tumor cells. RANKL induced cancer-
related gene modulation in osteosarcoma
(OS). However, the exact effect of this gene
modulation remains to be determined. OPG
indirectly inhibits bone tumor growth. 
role played by RANKL is not clear in primary bone
tumors such as osteosarcoma.
RANKL triggered directional migration of mature
osteoclasts towards a RANKL source (Jones et al.,
2006). Moreover, a positive correlation between constant
RANK expression with decreased/absent expression of
RANKL and a high metastatic phenotype has been
reported in breast carcinoma (Bhatia et al., 2005). In this
context, it appears that RANK-positive cells are starving
RANKL and are preferentially attracted to a RANKL
rich bone environment. It could therefore be
hypothesized that RANK expressed on tumor cells
represents a specific marker of bone metastasis.
The term ‘osteoimmunology’ was recently coined to
identify the collaboration between the field of bone
biology and immunology (Arron and Choi, 2000). Thus,
osteoimmunology is becoming increasingly important to
understand the pathogenesis and to develop new
therapeutic strategies affecting both systems.
Alternatively, RANKL could act as a protector of tumor
development, as it plays a role as a potent immune
activator by inhibiting dendritic cell apoptosis (Wong et
al., 1997). Further studies are needed to disclose the full
potential of RANK/RANKL in bone oncology as
therapeutic targets. 
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